Shares of Iovance Biotherapeutics, Inc. (IOVA) are down more than 14% Friday morning after the company said it received feedback from the Food and Drug Administration on the rolling Biologics License Application for Lifileucel, the company's investigational drug for melanoma.
The company said that as part of an amendment to the ongoing investigational new drug application submitted during the third quarter of 2022, it received recent FDA feedback regarding supplemental assay validation information and comparability data for lifileucel.
Iovance will address these FDA comments promptly and will now complete its rolling BLA submission during the first quarter of 2023, the company added.
IOVA, currently at $6.07, has traded in the range of $5.43-$20.60 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.